| Ytd | -29.31% | |
| 1y | 12.13% |
| Open | 21.99 | Prev Close | 21.93 | Low | 21.80 | High | 22.17 | Mkt Cap | 2.49B |
| Vol | 5.38M | Avg Vol | 1.90M | EPS | -3.40 | P/E | N/A | Forward P/E | -7.93 |
| Beta | 0.96 | Short Ratio | 12.04 | Inst. Own | 126.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 21.63 | 200-d Avg | 23.40 | 1yr Est | 36.63 |
VRDN News
Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lu
OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF)
Jupiter Topco LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) du
Biotechnology investing is a strange corner of the market. A company can own a drug that may even
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company
Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in the
Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) durin
OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond dri
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company
Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report)
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expa
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen'
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Thera
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company
Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Compa
OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or t
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developi